← Who reports today · Health Care
Gilead Sciences (GILD) earnings date & Q3 2026 results
Net income
$2,429M
down 20.4% y/y
Total revenues
$8,300M
up 6.8% y/y
Operating income
$3,462M
up 4.1% y/y
Next report
~ Feb 9
not announced yet
The quarter in brief
Gilead's Q3 2026 revenue rose 7% to $8.3 billion and operating income grew 4.1% to $3,462 million, but net income fell 20.4% to $2,429 million and diluted EPS dropped to $1.94 from $2.43.
Key growth driver: Product sales — the fastest-growing revenue line: $8,289, +13% y/y. · by the Q3 2026 report
- Net income −20.4% — net losses on equity securities versus gains a year ago, higher operating expenses and higher income tax
Source
«The decrease was primarily due to: • Net losses from equity securities in 2026 compared to net gains in 2025; • Higher operating expenses; and • Higher income tax expense; partially offset by»
Form 10-Q
All figures in $M.
| Line item | Amount and change |
|---|---|
| Product sales | $8,289 · +12.9% |
| Royalty, contract and other revenues | $11 · −97.4% |
| Total revenues | $8,300 · +6.8% |
| Cost of goods sold | $1,571 · +0.1% |
| Research and development expenses | $1,608 · +19.5% |
| Acquired in-process research and development expenses | $18 · −89.4% |
| Selling, general and administrative expenses | $1,641 · +20.9% |
| Operating income | $3,462 · +4.1% · 41.7% margin |
| Interest expense | $269 · +5.1% |
| Other (income) expense, net | $130 · vs $569 income |
| Income before income taxes | $3,063 · −15.9% |
| Income tax expense | $634 · +7.6% · 20.7% effective rate |
| Net income | $2,429 · −20.4% · $1.94/sh · 29.3% margin |
Verdict: Gilead's Q3 2026 revenue rose 7% to $8.3 billion and operating income grew 4.1% to $3,462 million, but net income fell 20.4% to $2,429 million and diluted EPS dropped to $1.94 from $2.43.
Gilead raised full-year 2026 product sales guidance to $31,000–$31,300 million from $30,100–$30,400 million, and lowered GAAP diluted EPS guidance to a loss of $(4.40)–$(4.05) from $(3.75)–$(3.40), including about $9.88 per share of acquired IPR&D charges of $12.4 billion. In Q3 2026 the company paid $1.0 billion in dividends, repurchased $370 million of stock and declared a Q4 dividend of $0.82 per share.
Source and notation
Source: Gilead Sciences press release, 8-K EX-99.1 of 10/29/2026 (SEC EDGAR).
Open as an image: Gilead Sciences (GILD), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Gilead Sciences (GILD) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/gild. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/gild"><img src="https://whoreportstoday.com/t/gild/img/gilead-sciences-gild-earnings-sankey.png" alt="Gilead Sciences (GILD) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/gild">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/gild/img/gilead-sciences-gild-earnings-sankey.png
<a href="https://whoreportstoday.com/t/gild">Gilead Sciences (GILD) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Equity securities swung to a net loss of $164 million from a gain of $483 million a year ago; other items were a $130 million expense versus $569 million of income.
- Product sales grew 13% to $8,289 million, while royalty, contract and other revenues fell to $11 million from $424 million.
- Veklury sales fell 69% to $86 million and Cell Therapy sales fell 18% to $355 million, while Trodelvy rose 42% to $506 million.
- Product gross margin improved to 81.0% from 78.6%.
- R&D expenses rose to $1,608 million from $1,346 million and SG&A to $1,641 million from $1,357 million, partly offset by acquired IPR&D falling to $18 million from $170 million; operating margin slipped to 41.7% from 42.8%.
- The effective tax rate rose to 20.7% from 16.2%.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Daniel P. O’DayChairman and Chief Executive Officer [1]
- Andrew D. DickinsonChief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Gileadsince 2016
- Chief Financial Officernow
- Head of Corporate Development and Strategy2016
- Lazarduntil 2016Global Co-Head of Healthcare Investment Banking
- MyogenGeneral Counsel and Vice President of Corporate Development
- GalapagosDirector
1 more
- Fosun Pharma and Kite joint ventureDirector
Source: SEC EDGAR: DEF 14A proxy statement, 2026-03-20 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-30 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-30 · SEC EDGAR · 11/18/2026
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. · Text: Wikipedia, CC BY-SA 4.0, abridged
It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. Market share (US pharma & biotech): ≈4% by TTM revenue.
Heads-up
- net income fell 20% y/y in Q3 2026
Net income for Q3 2026: $2,429M, −20% y/y. In the report's figures: costs grew faster than revenue: selling, general and administrative expenses +21% y/y, research and development expenses +20% y/y. The company explains: net losses on equity securities versus gains a year ago, higher operating expenses and higher income tax (Form 10-Q). Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
Same quarter a year ago (ended December 31, 2025): revenue $7.92B, EPS (GAAP) $1.75
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
GILD earnings history: past report dates
| Oct 29, 2026 Thu | 4:03 pmafter market close | Sep 30, 2026 | $8.3B+7% y/y | $1.94−20% y/y |
| Aug 4, 2026 Tue | 4:03 pmafter market close | Jun 30, 2026 | $7.8B+10% y/y | −$8.45 |
| May 7, 2026 Thu | 4:03 pmafter market close | Mar 31, 2026 | $7.0B+4% y/y | $1.61+55% y/y |
| Feb 10, 2026 Tue | 4:02 pmafter market close | Dec 31, 2025 | ≈$7.9B+5% y/y | ≈$1.75+22% y/y |
| Oct 30, 2025 Thu | 4:04 pmafter market close | Sep 30, 2025 | $7.8B+3% y/y | $2.43+143% y/y |
| Aug 7, 2025 Thu | 4:26 pmafter market close | Jun 30, 2025 | $7.1B+2% y/y | $1.56+21% y/y |
| Apr 24, 2025 Thu | 4:03 pmafter market close | Mar 31, 2025 | $6.7B−0% y/y | $1.04 |
| Feb 11, 2025 Tue | 4:04 pmafter market close | Dec 31, 2024 | ≈$7.6B+6% y/y | ≈$1.43+25% y/y |
| Nov 6, 2024 Wed | 4:09 pmafter market close | Sep 30, 2024 | $7.5B+7% y/y | $1.00−42% y/y |
| Aug 8, 2024 Thu | 4:06 pmafter market close | Jun 30, 2024 | $7.0B+5% y/y | $1.29+55% y/y |
| Apr 25, 2024 Thu | 4:04 pmafter market close | Mar 31, 2024 | $6.7B+5% y/y | −$3.34 |
| Feb 6, 2024 Tue | 4:04 pmafter market close | Dec 31, 2023 | ≈$7.1B−4% y/y | ≈$1.14−12% y/y |
| Nov 7, 2023 Tue | 4:03 pmafter market close | Sep 30, 2023 | $7.1B+0% y/y | $1.73+22% y/y |
| Aug 3, 2023 Thu | 4:07 pmafter market close | Jun 30, 2023 | $6.6B+5% y/y | $0.83−9% y/y |
| Apr 27, 2023 Thu | 4:05 pmafter market close | Mar 31, 2023 | $6.4B−4% y/y | $0.80 |
| Feb 2, 2023 Thu | 4:03 pmafter market close | Dec 31, 2022 | ≈$7.4B+2% y/y | ≈$1.30+333% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Gilead Sciences: 15-year financials
| 2025 | 29,443 | 10,022 | 8,510 | 9,456 | 4,003 |
| 2024 | 28,754 | 1,662 | 480 | 10,305 | 3,918 |
| 2023 | 27,116 | 7,605 | 5,665 | 7,421 | 3,809 |
| 2022 | 27,281 | 7,330 | 4,592 | 8,344 | 3,709 |
| 2021 | 27,305 | 9,918 | 6,225 | 10,805 | 3,605 |
| 2020 | 24,689 | 4,071 | 123 | 7,518 | 3,449 |
| 2019 | 22,449 | 4,287 | 5,386 | 8,319 | 3,222 |
| 2018 | 22,127 | 8,200 | 5,455 | 7,476 | 2,971 |
| 2017 | 26,107 | 14,124 | 4,628 | 11,308 | 2,731 |
| 2016 | 30,390 | 17,633 | 13,501 | 16,299 | 2,455 |
| 2015 | 32,639 | 22,193 | 18,108 | 20,503 | 1,874 |
| 2014 | 24,890 | 15,265 | 12,101 | 12,261 | 0 |
| 2013 | 11,202 | 4,524 | 3,075 | 2,971 | 0 |
| 2012 | 9,702 | 4,010 | 2,592 | 2,798 | — |
| 2011 | 8,385 | 3,790 | 2,804 | 3,507 | — |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Gilead Sciences: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 59,023 | 22,703 | 24,937 | 7,564 | 18,342 | 11,813 |
| 2024 | 58,995 | 19,330 | 26,710 | 9,991 | 19,173 | 12,004 |
| 2023 | 62,125 | 22,833 | 24,987 | 6,085 | 16,085 | 11,280 |
| 2022 | 63,171 | 21,240 | 25,229 | 5,412 | 14,443 | 11,237 |
| 2021 | 67,952 | 21,069 | 26,695 | 5,338 | 14,772 | 11,610 |
| 2020 | 68,407 | 18,202 | 31,402 | 5,997 | 15,996 | 11,397 |
| 2019 | 61,627 | 22,525 | 24,593 | 11,631 | 30,296 | 9,759 |
| 2018 | 63,675 | 21,387 | 27,322 | 17,940 | 35,836 | 10,605 |
| 2017 | 70,283 | 20,442 | 33,542 | 7,588 | 31,823 | 11,635 |
| 2016 | 56,977 | 18,887 | 26,346 | 8,229 | 19,588 | 9,218 |
| 2015 | 51,716 | 18,534 | 22,178 | 12,851 | 24,762 | 9,890 |
| 2014 | 34,664 | 15,426 | 12,404 | 10,027 | 17,714 | 5,761 |
| 2013 | 22,579 | 11,370 | 6,636 | 2,113 | 6,997 | 6,407 |
| 2012 | 21,240 | 9,303 | 8,224 | 1,804 | 6,156 | 4,238 |
| 2011 | 17,303 | 6,739 | 7,606 | 9,884 | 13,919 | 2,515 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 11,152 | 6,692 | +4,460 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 323 | 280 | |
| · incl. stock-based comp (non-cash)share-based compensation | 683 | 664 | |
| Capexpurchases of property & equipment | −494 | −358 | −136 |
| Free cash flow ≈operating cash flow − capex | 10,658 | 6,334 | +4,324 |
| Investing activities, netcapex, acquisitions, securities | −8,821 | −2,958 | −5,863 |
| · incl. acquisitionsbusinesses net of cash acquired | −11,337 | −461 | −10,876 |
| Financing activities, netdebt, buybacks, dividends | −3,423 | −6,482 | +3,059 |
| · incl. buybacksrepurchases of common stock | −1,144 | −1,692 | +548 |
| · incl. dividends paid | −3,108 | −3,009 | −99 |
| FX effect on cash | −34 | 87 | −121 |
| Net change in cash | −1,126 | −2,661 | +1,535 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $13.0B (25% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 2026Per the cover of its 2025 10-K, one class is registered — GILD common stock; the legal proceedings section contains no shareholder suits or SEC cases (only antitrust and product cases). sec.gov ↗
- Dec 2025Declared dividend per share has risen every year: $2.72 (2020), $2.92 (2022), $3.16 (2025) (XBRL 10-K). data.sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Dec 2025Diluted share count fell 0.6% over 2020→2025; SBC is 3.0% of revenue; buybacks of $1.9B in 2025 (XBRL 10-K). data.sec.gov ↗
Scoring: 2.0, no deductions = 2.0
- Share classes
- Single class of common stock (10-K cover).
- Dilution
- Diluted share count 2020→2025 −0.6%; SBC 3.0% of revenue; buybacks of $0.5–1.9B a year.
- Disclosure
- 10-Ks and 10-Qs filed on time, audited US GAAP financials; no deduction.
- Dividends
- Dividend paid since 2015 and raised every year: $2.72 (2020) → $3.16 (2025); no cuts.
- Lawsuits & regulators
- The 10-K lists antitrust (HIV drugs) and product suits — industry-wide, no deduction; no shareholder disclosure suits or SEC cases.
- Related parties
- In the 2026 proxy the board affirmed that directors have no conflicts of interest; no material related-party transactions.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Gilead Sciences (GILD) earnings: FAQ
When is GILD's next earnings date?
We have not yet seen an announcement of the date from Gilead Sciences (GILD). Based on last year's report on Feb 10, 2026, the next report is expected around Feb 9, 2027.
What time does GILD report earnings?
Gilead Sciences usually reports after market close: its latest results release was filed with the SEC at 4:03 pm ET on Oct 29, 2026.
When did GILD last report earnings?
Gilead Sciences reported Q3 2026 results on Oct 29, 2026.
Where can I find Gilead Sciences's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to GILD's filings; this page breaks the latest report down in a Sankey chart.
What was GILD's net income in Q3 2026?
Gilead Sciences reported net income of $2,429M for Q3 2026 (−20.4% year over year), under US GAAP.
Does Gilead Sciences pay dividends?
Yes. In 2025, Gilead Sciences paid $4,003M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Gilead Sciences's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.5x: $8,385M in 2011 and $29,443M in 2025. The peak was $32,639M in 2015. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: HCA · Q3 2026 · HSIC · Q3 2026 · HUM · Q2 2026 · IDXX · Q3 2026 · ILMN · Q3 2026 · INCY · Q2 2026 · IQV · Q3 2026 · ISRG · Q3 2026 · JNJ · Q3 2026 · LH · Q3 2026 · all reports